Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Non-treatment Seeking Heavy Drinkers
NCT04781322Phase 1Recruiting
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in alcohol-associated liver disease (ALD) comparing Alirocumab with Placebo (2 arms). Primary endpoint: Incidence and severity of treatment-emergent adverse events at 8 weeks. Started Oct 2021; status: recruiting.
02
Drugs
alirocumab
03
Conditions
alcohol-associated liver disease (ALD)
Beyond the preview
Go deeper on NCT04781322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781322.